ClinicalTrials.gg
CompletedNCT02206867Updated Jun 15, 2015

Pharmacokinetics and Safety Study of LBAL in Healthy Subjects

A Phase 1 interventional study of LBAL and Humira in Healthy Subjects, sponsored by LG Life Sciences. Completed. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-15.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

To compare PK, safety and tolerability of LBAL developed by LG Life Sciences Ltd. With those of Humira®.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

LG Life Sciences is the lead sponsor of 78 studies on the registry; none are open to participants now.

First submitted before LG Life Sciences became part of LG Chem.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 20-45 years old healthy males
  2. 19.0 \~ 28.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of current or latent tuberculosis (TB); history of severe active chronic or local infection including TB
  2. Severe infection (e.g. sepsis) requiring admission or antibiotics treatment within four weeks prior to administration
  3. previous or concomitant disease including hepatic, renal, neurological, respiratory, gastrointestinal, endocrine, hematologic, oncologic, cardiovascular, urinary, musculoskeletal or psychiatric, disease/disorders
  4. Chronic or relevant acute infections. A negative result for (HIV), (Hep B), and (Hep C) is required for participation (i.e. HIV Ab, HBsAg, HBcAb, HCV Ab)
  5. Fever greater than 38.3℃ within a week prior to administration of study drug
  6. Previous or current drug abuse
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    LBAL

    Developed by LG Life Sciences

    Biological: LBAL

  • Active comparator
    Humira®

    Abbvie

    Biological: Humira

Interventions

  • BiologicalLBAL

    Anti-inflammatory agents

    Also known as: Adalimumab

  • BiologicalHumira

    Anti-inflammatory agents

    Also known as: Adalimumab

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of the analyte in serum over the time interval from 0 extrapolated to infinity

    Time frame: 0 to 65 days

  2. Maximum measured concentration of the analyte in serum

    Time frame: 0 to 65 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2014
First posted
Aug 1, 2014
Start
Aug 2014
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Jun 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02206867
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Aug 1, 2014
Start date
Aug 2014
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Jun 15, 2015

Study contacts

Kyung-Sang Yu, M.D., Ph.D., M.B.A
principal investigator · Dep. of Clnical Pharmacology, Seoul National University College of Medicine and Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion